Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial...

First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...

One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...

One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...